National Institute on Drug Abuse; Notice of Closed Meetings, 57918-57919 [2022-20529]

Download as PDF jspears on DSK121TN23PROD with NOTICES 57918 Federal Register / Vol. 87, No. 183 / Thursday, September 22, 2022 / Notices Name of Committee: Biology of Development and Aging Integrated Review Group; Mechanisms of Cancer Therapeutics A Study Section. Date: October 24–25, 2022. Time: 8:00 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Place: Hyatt Regency Bethesda, 1 Bethesda Metro Center, Bethesda, MD 20814. Contact Person: Careen K Tang-Toth, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6214, MSC 7804, Bethesda, MD 20892, (301) 435– 3504, tothct@csr.nih.gov. Name of Committee: Brain Disorders and Clinical Neuroscience Integrated Review Group; Pathophysiology of Eye Disease—1 Study Section. Date: October 24–25, 2022. Time: 9:00 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Place: Canopy by Hilton, 940 Rose Avenue, North Bethesda, MD 20852. Contact Person: Afia Sultana, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4189, Bethesda, MD 20892, (301) 827–7083, sultanaa@mail.nih.gov. Name of Committee: Infectious Diseases and Immunology A Integrated Review Group; Virology—B Study Section. Date: October 25–26, 2022. Time: 8:00 a.m. to 7:30 p.m. Agenda: To review and evaluate grant applications. Place: Hotel Monaco, 700 F Street NW, Washington, DC 20001. Contact Person: Neerja Kaushik-Basu, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3198, MSC 7808, Bethesda, MD 20892, (301) 435– 1742, kaushikbasun@csr.nih.gov. Name of Committee: Biological Chemistry and Macromolecular Biophysics Integrated Review Group; Macromolecular Structure and Function A Study Section. Date: October 25–26, 2022. Time: 8:30 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: American Inn of Bethesda, 8130 Wisconsin Ave., Bethesda, MD 20814. Contact Person: Ian Frederick Thorpe, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 903K, Bethesda, MD 20892, (301) 480–8662, ian.thorpe@nih.gov. Name of Committee: Cardiovascular and Respiratory Sciences Integrated Review Group; Integrative Myocardial Physiology/ Pathophysiology B Study Section. Date: October 25–26, 2022. Time: 9:00 a.m. to 6:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Kirk E Dineley, Ph.D., Scientific Review Officer, Center for VerDate Sep<11>2014 17:32 Sep 21, 2022 Jkt 256001 Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 806E, Bethesda, MD 20892, (301) 867–5309, dineleyke@csr.nih.gov. Name of Committee: Bioengineering Sciences & Technologies Integrated Review Group; Gene and Drug Delivery Systems Study Section. Date: October 25–26, 2022. Time: 9:00 a.m. to 7:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Jain Krotz, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (240) 672–8670, jain.krotz@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: September 19, 2022. Miguelina Perez, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2022–20563 Filed 9–21–22; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Aging; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Aging Special Emphasis Panel; ‘‘ADRD Proteinopathies’’. Date: November 1, 2022. Time: 11:30 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Dario Dieguez, Ph.D., Scientific Review Officer, Scientific Review PO 00000 Frm 00055 Fmt 4703 Sfmt 4703 Branch, National Institutes of Health, National Institute on Aging, Bethesda, MD 20814, (301) 827–3101, dario.dieguez@ nih.gov. Information is also available on the Institute’s/Center’s home page: www.nia.nih.gov/, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS) Dated: September 19, 2022. Miguelina Perez, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2022–20557 Filed 9–21–22; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Accelerating the Pace of Drug Abuse Research Using Existing Data. Date: October 27–28, 2022. Time: 11 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Li Rebekah Feng, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Activities, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 827–7245, rebekah.feng@nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Increasing Immediate Engagement and Retention in HIV Treatment with Substance Users. Date: October 27, 2022. Time: 1 p.m. to 2 p.m. E:\FR\FM\22SEN1.SGM 22SEN1 Federal Register / Vol. 87, No. 183 / Thursday, September 22, 2022 / Notices jspears on DSK121TN23PROD with NOTICES Agenda: To review and evaluate grant applications. Place: National Institutes of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Marisa Srivareerat, Ph.D., Scientific Review Officer, Scientific Review Branch, Office of Extramural Policy, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 435–1258, marisa.srivareerat@nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program. Date: November 2, 2022. Time: 3 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Brian Stefan Wolff, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Research, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 480–1448, brian.wolff@nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1—Clinical Trial Allowed). Date: November 29, 2022. Time: 9:45 a.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Marisa Srivareerat, Ph.D., Scientific Review Officer, Scientific Review Branch, Office of Extramural Policy, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 435–1258, marisa.srivareerat@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: September 16, 2022. Tyeshia M. Roberson-Curtis, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2022–20529 Filed 9–21–22; 8:45 am] BILLING CODE 4140–01–P VerDate Sep<11>2014 17:32 Sep 21, 2022 Jkt 256001 DEPARTMENT OF HOMELAND SECURITY [Docket No. DHS–2022–0047] Homeland Security Advisory Council Office of Partnership and Engagement (OPE), Department of Homeland Security (DHS). ACTION: Notice of partially closed federal advisory committee meeting. AGENCY: The Homeland Security Advisory Council (HSAC or Council) will meet virtually via teleconference on Thursday, October 6, 2022. The meeting will be partially closed to the public. DATES: The meeting will take place from 1:30 p.m. to 3:00 p.m. ET on Thursday, October 6, 2022. The meeting will be closed to the public from 1:45 p.m. to 3:00 p.m. EDT. The meeting will be open to the public from 1:30 p.m. to 1:45 p.m. EDT. The meeting may end early if the Council has completed its business. Public Participation: Members of the public will be in listen-only mode. The public may register to participate in the open session of this meeting via teleconference through the following procedures. Each person must provide their full legal name and email address no later than 5:00 p.m. EDT on Tuesday, October 4, 2022 to the individual listed in the FOR FURTHER INFORMATION CONTACT section. The conference call details will be provided to interested members of the public after the public registration period closes and prior to the start of the meeting. For information on services for individuals with disabilities, or to request special assistance, contact the individual listed in the FOR FURTHER INFORMATION CONTACT section as soon as possible. Written public comments prior to the meeting must be received by 5:00 p.m. EDT on Tuesday, October 4, 2022, and must be identified by Docket No. DHS– 2022–0047. Written public comments after the meeting must be identified by Docket No. DHS–2022–0047 and may be submitted by one of the following methods: • Federal eRulemaking Portal: https:// www.regulations.gov. Follow the instructions for submitting comments. • Email: HSAC@hq.dhs.gov. Include Docket No. DHS–2022–0047 in the subject line of the message. • Mail: Rebecca Sternhell, Executive Director of Homeland Security Advisory Council, Office of Partnership and Engagement, Mailstop 0385, Department of Homeland Security, 2707 Martin Luther King Jr Ave SE, Washington, DC 20528. SUMMARY: PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 57919 Instructions: All submissions received must include the words ‘‘Department of Homeland Security’’ and ‘‘DHS–2022– 0047,’’ the docket number for this action. Comments received will be posted without alteration at https:// www.regulations.gov, including any personal information provided. You may wish to review the Privacy and Security Notice which is available via a link on the homepage of https:// www.regulations.gov. Docket: You may provide your comments and read comments received by the Council, by going to https:// www.regulations.gov, searching ‘‘DHS– 2022–0047,’’ and selecting ‘‘Open Docket Folder.’’ FOR FURTHER INFORMATION CONTACT: Rebecca Sternhell at 202–891–2876 or HSAC@hq.dhs.gov. SUPPLEMENTARY INFORMATION: Notice of this meeting is given under Section 10(a) of the Federal Advisory Committee Act (FACA), Public Law 92–463 (5 U.S.C. appendix), which requires a portion of each FACA committee meeting to be open to the public unless the President, or the head of the agency to which the advisory committee reports, determines that a portion of the meeting may be closed to the public in accordance with 5 U.S.C. 552b(c). The Council provides organizationally independent, strategic, timely, specific, actionable advice, and recommendations to the Secretary of Homeland Security on matters related to homeland security. The Council consists of senior executives from government, the private sector, academia, law enforcement, and nongovernmental organizations. The Council will meet in an open session between 1:30 p.m. to 1:45 p.m. ET. During the open session, the Council will receive a progress report from the Customer Experience and Service Delivery subcommittee. The Council will meet in a closed session from 1:45 p.m. to 3:00 p.m. ET to participate in a sensitive discussion with DHS Secretary Alejandro N. Mayorkas regarding DHS operations. Basis for Partial Closure: In accordance with Section 10(d) of FACA, the Secretary of Homeland Security has determined this meeting must be closed during this session as the disclosure of the information relayed would be detrimental to the public interest for the following reasons: The Council will participate in a sensitive operational discussion containing For Official Use Only and Law Enforcement Sensitive information. This discussion will include information regarding threats facing the E:\FR\FM\22SEN1.SGM 22SEN1

Agencies

[Federal Register Volume 87, Number 183 (Thursday, September 22, 2022)]
[Notices]
[Pages 57918-57919]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-20529]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Accelerating the Pace of Drug Abuse Research Using 
Existing Data.
    Date: October 27-28, 2022.
    Time: 11 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Li Rebekah Feng, Ph.D., Scientific Review 
Officer, Scientific Review Branch, Division of Extramural 
Activities, National Institute on Drug Abuse, NIH, 301 North 
Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 827-7245, 
[email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Increasing Immediate Engagement and Retention in HIV 
Treatment with Substance Users.
    Date: October 27, 2022.
    Time: 1 p.m. to 2 p.m.

[[Page 57919]]

    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Marisa Srivareerat, Ph.D., Scientific Review 
Officer, Scientific Review Branch, Office of Extramural Policy, 
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, 
MSC 6021, Bethesda, MD 20892, (301) 435-1258, 
[email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Coordinating Center for the HIV/AIDS and Substance 
Use Cohorts Program.
    Date: November 2, 2022.
    Time: 3 p.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Brian Stefan Wolff, Ph.D., Scientific Review 
Officer, Scientific Review Branch, Division of Extramural Research, 
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, 
MSC 6021, Bethesda, MD 20892, (301) 480-1448, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Avenir Award Program for Chemistry and Pharmacology 
of Substance Use Disorders (DP1--Clinical Trial Allowed).
    Date: November 29, 2022.
    Time: 9:45 a.m. to 6 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Marisa Srivareerat, Ph.D., Scientific Review 
Officer, Scientific Review Branch, Office of Extramural Policy, 
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, 
MSC 6021, Bethesda, MD 20892, (301) 435-1258, 
[email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist 
Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse National Research Service Awards for Research Training; 
93.279, Drug Abuse and Addiction Research Programs, National 
Institutes of Health, HHS)

    Dated: September 16, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-20529 Filed 9-21-22; 8:45 am]
BILLING CODE 4140-01-P